Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections San Francisco, CA March 9-12 2025 Back

Tweet

Weight Change on F/TAF Versus Placebo: Using Common F/TDF Groups to Bridge Data Across Clinical Trials       David Glidden1, Andrew Whiteman2, Yuan Tian2, Andrea Marongiu3, Joshua Gruber2, Cal Cohen2   1University of California San Francisco, San Francisco, CA, USA; 2Gilead Sciences, Inc., Foster City, CA, USA; 3Gilead Sciences Ltd, Uxbridge, UK